Atherosclerotic plaque stabilization and regression: a review ...
2024年1月4日 · In this Review, Sarraju and Nissen summarize the clinical trial evidence for coronary atherosclerotic plaque stabilization and regression with plasma LDL-cholesterol-lowering therapy and other...
Stabilization of high-risk plaques - PMC - PubMed Central (PMC)
2015年10月3日 · We reviewed important findings regarding plaque vulnerability and some encouraging emerging approaches for plaque stabilization. Keywords: Atherosclerotic cardiovascular diseases (ASCVDs), inflammation, low-density lipoprotein cholesterol (LDL-C), statins, thin-cap fibroatheroma (TCFA)
Stabilization of atherosclerotic plaques: an update ...
2013年8月21日 · Plaque stabilization can be achieved by increasing thickness of fibrous cap, reducing inflammation in the fibrous cap, and reducing size of atheromatous core. Plaques may be stabilized against thrombosis independent of changes in plaque size and luminal obstruction.
Atherosclerotic plaque stabilization and regression: a review ...
Since 2016, newer and potent lipid-lowering strategies, such as proprotein convertase subtilisin-kexin type 9 inhibition, have shown incremental effects on plaque regression and risk of clinical events.
Mechanisms of plaque stabilization with statins - American ...
2003年2月20日 · Struck by the consistent angiographic findings of modest reduction in luminal obstruction with statin treatment, we reasoned that lipid lowering might prevent clinical events by changing atherosclerotic plaque in a qualitative manner, independent of changes in lesion size.
Plaque stabilisation by systemic and local drug administration
Plaque stabilisation can be defined by any intervention or interaction which, by causing a change in either the structure, content or function of an atherosclerotic plaque and/or the overlying endothelium, will either prevent or reduce the severity of erosion or rupture.
Strategies to achieve coronary arterial plaque stabilization
1999年2月1日 · Lipid lowering agents, β-adrenergic blockers, angiotensin converting enzyme inhibitors and antioxidants have been shown to reduce the incidence of acute coronary syndromes, presumably through plaque stabilization.